GTBP - GT Biopharma announces strong early-stage safety results for blood cancer therapy

Mohammed Haneefa Nizamudeen/iStock via Getty Images GT Biopharma ([[GTBP]] +6.0%) announced interim results from a Phase 1 trial for the company’s recombinant fusion protein conjugate, GTB-3550 in the treatment of high-risk myelodysplastic syndromes ((MDS)) and refractory/relapsed acute myeloid leukemia ((AML)). With 11 patients completing the treatment, GTB-3550 was well-tolerated with no cytokine release syndrome detected, the company said. 57% of patients were found to have a significant reduction in AML/MDS cancer cells at doses ranging from 25mcg/kg/day to 150mcg/kg/day. Some patients had a 63.7% reduction in bone marrow blast levels. “In addition to strong safety results, we have seen significant reductions in CD33+ cancer cells in four of the last seven patients (57%) treated with doses of GTB-3550 ranging from 25mcg/kg/day to 150mcg/kg/day,” noted GT Biopharma CEO, Anthony Cataldo. In April, GT Biopharma announced the appointment of industry veteran and its former board member Gregory Berk as the new chief medical

For further details see:

GT Biopharma announces strong early-stage safety results for blood cancer therapy